Extramedullary AML: Clinical and Molecular Features
Leukemia patients with cancer spreading outside bone marrow face much shorter survival, highlighting why genetic testing and tailored treatment strategies matter for this aggressive form.
This propensity score-matched retrospective study of 617 AML patients from Princess Margaret Cancer Centre demonstrates that extramedullary AML is a high-risk entity with dramatically shorter overall survival (14.2 vs 64.1 months) and higher relapse rates despite achieving higher initial response rates. The study independently validates EMD as a poor prognostic factor (OS HR 1.79, EFS HR 1.95) and highlights NPM1 mutations and t(8;21) enrichment in EMD-AML, underscoring the need for molecular profiling and novel treatment strategies.
What the study was
- Study design
- Retrospective cohort study with propensity score matching
- Population
- Adults with newly diagnosed AML (2005–2018), Princess Margaret Cancer Centre
- Sample size
- 617
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cancers (Basel)
Why it surfaced
Largest propensity-matched EMD-AML series to date; fills important evidence gap with clear clinical relevance for AML management decisions. Retrospective design limits to STANDARD.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.